about
Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cellsGut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunityOxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-AcetylcysteinePathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel diseaseThe diagnosis of primary biliary cirrhosisGut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectivesToll-like receptors in pathophysiology of liver diseasesNLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretionCheck MAIT.Subanesthetic isoflurane reduces zymosan-induced inflammation in murine Kupffer cells by inhibiting ROS-activated p38 MAPK/NF-κB signaling.The microbiota regulates susceptibility to Fas-mediated acute hepatic injuryMetagenomic cross-talk: the regulatory interplay between immunogenomics and the microbiome.Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease.Inflammasomes and the microbiota--partners in the preservation of mucosal homeostasis.The role of the microbiota in inflammation, carcinogenesis, and cancer therapy.Commensal microbiota is hepatoprotective and prevents liver fibrosis in miceIs intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?Gut microbiota modulate the immune effect against hepatitis B virus infection.Effect of Lipopolysaccharide on the Progression of Non-Alcoholic Fatty Liver Disease in High Caloric Diet-Fed Mice.Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocolMicrobiome and potential targets for chemoprevention of esophageal adenocarcinoma.Adipocytes as a Link Between Gut Microbiota-Derived Flagellin and Hepatocyte Fat Accumulation.Role of intestinal microbiota and metabolites on gut homeostasis and human diseases.The Gut Microbiota as a Therapeutic Target in IBD and Metabolic Disease: A Role for the Bile Acid Receptors FXR and TGR5.The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen/CD1d-dependent manner.Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease.An overview of advanced technologies for selection of probiotics and their expediency: A review.Functional Immune Anatomy of the Liver-As an Allograft.Omics for Understanding the Gut-Liver-Microbiome Axis and Precision Medicine.Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease.Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment.Targeting Hepatic Fibrosis in Autoimmune Hepatitis.Microbiome-Modulated Metabolites at the Interface of Host Immunity.The challenge of treating orphan disease.Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis.Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitisNew avenues to treatment of liver cirrhosis.Reduction of venous pressure during the resection of liver metastases compromises enteric blood flow: IGFBP-1 as a novel biomarker of intestinal barrier injury.Unique topics and issues in rheumatology and clinical immunology.Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients.
P2860
Q26753022-4E00DEDF-330A-4965-8CAE-45E56B7EA829Q26773267-CCD0FAAF-7A87-4C0F-89D7-5C1C904E1DC3Q26773384-F1042FC3-FE0B-4299-BD71-D2578470EA13Q26777414-13382A54-ECA3-4337-ACC9-78E19F9682F9Q26829493-256A8F9B-06CD-4B30-B493-C10021A51128Q26864127-86F70959-9919-4A8E-99D3-2C6E78D94244Q28070077-1E51620F-5E34-4B4B-9366-194716CAA43CQ28512429-AA5025D4-41C1-48ED-9BD2-0DD1A52BCB5EQ33630962-D933C7ED-0E1B-4B27-80E2-6B85BF922EA0Q34053083-F8314112-681F-42AB-8FA3-63F93A72D5DAQ34122986-51152C0F-66B1-4274-8803-C4F5AA9DDA67Q34502460-4E765714-1B38-4E29-A7F5-8E34EC6929A9Q34750494-FC534786-5D67-44EE-B3BA-7A1225930E03Q35332035-90682CC6-CF6A-440B-AD5E-5A31248FC495Q35346303-E4A8BE0D-E093-44BA-B18D-598007D34FC1Q35481673-C8AA0549-9817-4BFD-9E38-EB24AEF746CDQ35667925-740A8E4E-21E9-4339-BF5B-319B5574BBC8Q35745517-8F1990C4-E32C-4F74-B27C-0865DCF949CEQ35829297-124C611B-B661-4C31-BA80-3AC613BDC5BBQ35860576-182BC3E9-54EA-43BF-8D99-7B7A82AFB644Q35954977-3323F485-E1AD-4C39-97E1-35C1AC629DAAQ35976370-D268DD87-1C98-4C2D-B1F4-BE703F2B0708Q36243299-A76B327B-B50E-4ED6-A0C3-F423057BD477Q37255981-6E401FE2-E231-4619-A55D-9D17A32CA576Q37581353-9F7CD81C-C5F6-4B4E-B5DC-B9F541EAA213Q38202220-E00F6B16-A1B3-4B84-BE01-B96D311086EAQ38617028-59CBCF92-2015-4062-A18C-D88A3E164E87Q38723925-DB948B62-8767-479A-B7D0-33CCF055A50CQ38750137-2512154F-4E37-4699-BA5C-DF8D06B6009EQ38782413-2D7A77D3-4A29-4F34-BC08-B9654BD96FE8Q38872713-E02DAF5F-EACE-4918-ABA4-46ADB037C4BFQ38902371-E2DB0BAB-290B-4B1A-A24A-EC45881C77CBQ39030609-4CDA2EC0-28DD-49EF-B880-C632C9DEE2DEQ39098238-0432D333-CCBC-43E8-BD33-FB4D184522D0Q40044046-BC1D7EA4-1210-4C1F-94E7-97CBA1F2B262Q42369219-17D26712-5580-4804-8A69-CCB168E987E8Q44004240-BF645FFA-BA63-4319-B6EA-ADD801EB24C7Q46096756-1915C35E-E5EC-47CA-89D9-DA5472422F26Q46941311-28B026CE-4595-4908-B93E-2100C32C5EC9Q47098813-F8EFD34B-F817-4732-AB0B-678ED1D41893
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Role of the intestinal microbiome in liver disease.
@ast
Role of the intestinal microbiome in liver disease.
@en
type
label
Role of the intestinal microbiome in liver disease.
@ast
Role of the intestinal microbiome in liver disease.
@en
prefLabel
Role of the intestinal microbiome in liver disease.
@ast
Role of the intestinal microbiome in liver disease.
@en
P2093
P1476
Role of the intestinal microbiome in liver disease.
@en
P2093
Christoph A Thaiss
Eran Elinav
Jorge Henao-Mejia
Paula Licona-Limon
Richard A Flavell
P356
10.1016/J.JAUT.2013.07.001
P577
2013-09-24T00:00:00Z